Development of a novel patient-reported measure for acromegaly: the Acro-TSQ

[1]  M. Fleseriu,et al.  Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update. , 2018, Endocrine reviews.

[2]  M. Fleseriu,et al.  Updates in Diagnosis and Treatment of Acromegaly , 2018, European endocrinology.

[3]  P. Chanson,et al.  A Consensus Statement on acromegaly therapeutic outcomes , 2018, Nature Reviews Endocrinology.

[4]  L. Naves,et al.  Cognitive-behavioral therapy improves the quality of life of patients with acromegaly , 2018, Pituitary.

[5]  X. Badia,et al.  Patient-centered assessment on disease burden, quality of life, and treatment satisfaction associated with acromegaly , 2017, Journal of Investigative Medicine.

[6]  X. Badia,et al.  Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegaly , 2017, Pituitary.

[7]  G. Stalla,et al.  Predictors of Quality of Life in Acromegaly: No Consensus on Biochemical Parameters , 2017, Front. Endocrinol..

[8]  I. Kreitschmann-Andermahr,et al.  PREDICTORS OF QUALITY OF LIFE IN 165 PATIENTS WITH ACROMEGALY: RESULTS FROM A SINGLE-CENTER STUDY. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[9]  I. Kreitschmann-Andermahr,et al.  University of Birmingham Patient reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly , 2016 .

[10]  M. Ruchała,et al.  Patient satisfaction and preferences of lanreotide Autogel treatment in acromegaly. , 2016, Endokrynologia Polska.

[11]  S. Joshi,et al.  A STUDY TO DEVELOP A NOVEL PATIENT-REPORTED ( PRO ) INSTRUMENT TO ASSESS SATISFACTION WITH ACROMEGALY TREATMENT : THE ACRO-TSQ , 2016 .

[12]  I. Kreitschmann-Andermahr,et al.  Diagnosis and management of acromegaly: the patient’s perspective , 2016, Pituitary.

[13]  C. Poiană,et al.  Current therapies and mortality in acromegaly , 2015, Journal of medicine and life.

[14]  P. Chanson,et al.  SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice—development and results from a pilot study , 2015, Pituitary.

[15]  A. Hoffman,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: MANAGEMENT OF ACROMEGALY PATIENTS: WHAT IS THE ROLE OF PRE-OPERATIVE MEDICAL THERAPY? , 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[16]  E. Laws,et al.  Acromegaly: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.

[17]  S. Melmed,et al.  Acromegaly: assessing the disorder and navigating therapeutic options for treatment. , 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[18]  P. Kadıoğlu,et al.  Impact of treatment satisfaction on quality of life of patients with acromegaly , 2014, Pituitary.

[19]  B. Wolffenbuttel,et al.  Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly. , 2011, European journal of endocrinology.

[20]  N. Leidy,et al.  Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1--eliciting concepts for a new PRO instrument. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[21]  Elizabeth Molsen,et al.  Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2--assessing respondent understanding. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[22]  A. J. van der Lely,et al.  Pegvisomant and Improvement of Quality of Life in Acromegalic Patients , 2011, Hormone Research in Paediatrics.

[23]  M. Molitch,et al.  Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly , 2009, Pituitary.

[24]  S. Melmed.  Acromegaly pathogenesis and treatment. , 2009, The Journal of clinical investigation.

[25]  P. Chanson,et al.  Guidelines for acromegaly management: an update. , 2009, The Journal of clinical endocrinology and metabolism.

[26]  X. Badia,et al.  Treatment of acromegaly improves quality of life, measured by AcroQol , 2007, Clinical endocrinology.

[27]  E. Christ,et al.  Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL) , 2005, Clinical endocrinology.

[28]  X. Badia,et al.  Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. , 2005, The Journal of clinical endocrinology and metabolism.

[29]  X. Badia,et al.  Acromegaly Quality of Life Questionnaire (AcroQoL) , 2004, Health and quality of life outcomes.

[30]  M. Atkinson,et al.  Health and Quality of Life Outcomes , 2004 .

[31]  X. Badia,et al.  Acromegaly Quality of Life Questionnaire (ACROQOL) a new health‐related quality of life questionnaire for patients with acromegaly: development and psychometric properties , 2002, Clinical endocrinology.

[32]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .